| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology, Vol 108, 31-39, Copyright © 1981 by Endocrine Society
ARTICLES |
FA Momany, CY Bowers, GA Reynolds, D Chang, A Hong and K Newlander
Experimental observations showed that the analogs [D-Trp2]- and [D- Phe2]methionine enkephalin amide were weakly active in releasing GH from rat pituitary in vitro. These observations were used to design more active GH-releasing factors. Conformational energy calculations were carried out, and energetically favored conformations of these polypeptides were found. Structural similarities as well as structural differences between active and inactive analogs were examined, and new sequences were predicted. Progressively more active analogs were designed, then synthesized, and tested. This cycle of steps was repeated, each time using structural and chemical concepts as design guides, until a series of very active analogs resulted. The most active analog to date, Tyr-D-Trp-Ala-Trp-D-Phe-NH2, was shown to release GH in vitro at 10-30 ng/ml medium, which is approximately 10(3) times more active than the two starting enkephalin-based analogs. From the structure-activity data, a mechanism for binding at the receptors is formulated, and a comparison is made between the structural relationships of the GH-releasing peptide analogs and the GH inhibitor, somatostatin.
This article has been cited by other articles:
![]() |
J. O. L. Jorgensen A simple twist of science: the convoluted tale of ghrelin continues. J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3279 - 3280. [Full Text] [PDF] |
||||
![]() |
M. Kojima and K. Kangawa Ghrelin: Structure and Function Physiol Rev, April 1, 2005; 85(2): 495 - 522. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Helmling, C. Maasch, D. Eulberg, K. Buchner, W. Schroder, C. Lange, S. Vonhoff, B. Wlotzka, M. H. Tschop, S. Rosewicz, et al. Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer PNAS, September 7, 2004; 101(36): 13174 - 13179. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. van der Lely, M. Tschop, M. L. Heiman, and E. Ghigo Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin Endocr. Rev., June 1, 2004; 25(3): 426 - 457. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Sun, P. Wang, H. Zheng, and R. G. Smith Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor PNAS, March 30, 2004; 101(13): 4679 - 4684. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Frago, C. Paneda, S. L. Dickson, A. K. Hewson, J. Argente, and J. A. Chowen Growth Hormone (GH) and GH-Releasing Peptide-6 Increase Brain Insulin-Like Growth Factor-I Expression and Activate Intracellular Signaling Pathways Involved in Neuroprotection Endocrinology, October 1, 2002; 143(10): 4113 - 4122. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tschop, M. A. Statnick, T. M. Suter, and M. L. Heiman GH-Releasing Peptide-2 Increases Fat Mass in Mice Lacking NPY: Indication for a Crucial Mediating Role of Hypothalamic Agouti-Related Protein Endocrinology, February 1, 2002; 143(2): 558 - 568. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Horvath, S. Diano, P. Sotonyi, M. Heiman, and M. Tschop Minireview: Ghrelin and the Regulation of Energy Balance--A Hypothalamic Perspective Endocrinology, October 1, 2001; 142(10): 4163 - 4169. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Korbonits, S. A. Bustin, M. Kojima, S. Jordan, E. F. Adams, D. G. Lowe, K. Kangawa, and A. B. Grossman The Expression of the Growth Hormone Secretagogue Receptor Ligand Ghrelin in Normal and Abnormal Human Pituitary and Other Neuroendocrine Tumors J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 881 - 887. [Abstract] [Full Text] |
||||
![]() |
O. C. Palyha, S. D. Feighner, C. P. Tan, K. K. McKee, D. L. Hreniuk, Y.-D. Gao, K. D. Schleim, L. Yang, G. J. Morriello, R. Nargund, et al. Ligand Activation Domain of Human Orphan Growth Hormone (GH) Secretagogue Receptor (GHS-R) Conserved from Pufferfish to Humans Mol. Endocrinol., January 1, 2000; 14(1): 160 - 169. [Abstract] [Full Text] |
||||
![]() |
E. E. Muller, V. Locatelli, and D. Cocchi Neuroendocrine Control of Growth Hormone Secretion Physiol Rev, April 1, 1999; 79(2): 511 - 607. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nielsen, S. Mellemkjær, L. M. Rasmussen, T. Ledet, J. Astrup, J. Weeke, and J. O. L. Jørgensen Gene Transcription of Receptors for Growth Hormone-Releasing Peptide and Somatostatin in Human Pituitary Adenomas J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2997 - 3000. [Abstract] [Full Text] |
||||
![]() |
R. G. Smith, L. H. T. Van der Ploeg, A. D. Howard, S. D. Feighner, K. Cheng, G. J. Hickey, M. J. Wyvratt Jr., M. H. Fisher, R. P. Nargund, and A. A. Patchett Peptidomimetic Regulation of Growth Hormone Secretion Endocr. Rev., October 1, 1997; 18(5): 621 - 645. [Abstract] [Full Text] |
||||
![]() |
S. E. Kirk, B. J. Gertz, S. H. Schneider, M. L. Hartman, S. S. Pezzoli, J. M. Wittreich, D. A. Krupa, J. R. Seibold, and M. O. Thorner Effect of Obesity and Feeding on the Growth Hormone (GH) Response to the GH Secretagogue L-692,429 in Young Men J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 1154 - 1159. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |